How do you pack 20 years of ADC learnings into one company? Tubulis has $63M more to answer that

Amber Tong

More than two decades have passed since the first antibody-drug conjugate went on the market. But according to a biotech startup out of Germany, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

How do you pack 20 years of ADC learnings into one company? Tubulis has $63M more to answer that

Amber Tong

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

How do you pack 20 years of ADC learn­ings in­to one com­pa­ny? Tubu­lis has $63M more to an­swer that

Amber Tong

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

How do you pack 20 years of ADC learnings into one company? Tubulis has $63M more to answer that

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?